Holen Sie sich die Stockscreener-App
223.43
2.01%
4.41
Handel nachbörslich:
222.03
-1.40
-0.63%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$219.02
Offen:
$218.75
24-Stunden-Volumen:
6.05M
Relative Volume:
0.95
Marktkapitalisierung:
$394.89B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.20B
KGV:
94.39
EPS:
2.3671
Netto-Cashflow:
$19.68B
1W Leistung:
+0.19%
1M Leistung:
-0.22%
6M Leistung:
+13.82%
1J Leistung:
+15.78%
1-Tages-Spanne:
$218.50
$225.82
1-Wochen-Bereich:
$204.27
$229.78
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.43 | 387.09B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
LLY
Lilly Eli Co
|
1,058.18 | 913.67B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.99 | 572.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
MRK
Merck Co Inc
|
121.93 | 297.22B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
AZN
Astrazeneca Plc
|
193.03 | 290.15B | 58.07B | 9.40B | 9.87B | 3.0115 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
DOJ Drops Challenge To AbbVie's $1.6B Break Fee Deduction - Law360
AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next - TechStock²
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological CancersLupin | Press Release - lupin.com
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week - Seeking Alpha
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next - TechStock²
AbbVie (ABBV) Receives a Buy from Guggenheim - The Globe and Mail
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
AbbVie upgraded by Moody’s to A2 with stable outlook - Investing.com Nigeria
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on AbbVie stock - Investing.com
Evercore ISI Group Lowers Price Target for AbbVie (ABBV) to $228 - GuruFocus
(02/06/26) Top Picks 2026: AbbVie Inc. (ABBV) - moneyshow.com
AbbVie Earnings Call: New Growth Engines Take Lead - The Globe and Mail
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss - TechStock²
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game - BioPharma Dive
Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating - marketscreener.com
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal - Finviz
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal - The Globe and Mail
AbbVie (ABBV) Receives a Neutral Rating as UBS Lowers Price Targ - GuruFocus
UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating - marketscreener.com
AbbVie Submits Regulatory Applications for Rinvoq in Patients with Vitiligo - Contract Pharma
AbbVie: The Market Is Getting It Wrong - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript - Insider Monkey
AbbVie shares slide on perceived Humira reliance - The Pharma Letter
AbbVie Shares Fall as Wall Street Focuses on Filler Weakness - The Business of Fashion
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds - Finviz
Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth - TradingView
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything But It's A Lot (NYSE:ABBV) - Seeking Alpha
AbbVie Earnings: Skyrizi Holds Steady Share Despite Competition - morningstar.com
AbbVie Inc. (ABBV) Shares Slide as Revenue Beat and Raised 2026 Outlook Fail to Stem Sell-Off - AlphaStreet News -
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - The Globe and Mail
AbbVie Q4 Earnings Call Highlights - Yahoo Finance
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise (ABBV) - Seeking Alpha
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake (NYSE:ABBV) - Seeking Alpha
AbbVie’s Deal Focus Is Not Just Early-Stage Assets - Citeline News & Insights
ABBV AbbVie Inc. Feb 2026 Evercore Maintains Outperform, PT lowered to $228 - Meyka
AbbVie Inc (ABBV) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
AMD, AbbVie, Boston Scientific, Eli Lilly, MP, Super Micro, Palantir, and More Movers - Barron's
AbbVie forecasts upbeat 2026 profit, but shares fall on key drug’s sales miss - WTVB
AbbVie’s Rinvoq Vitiligo Bid Raises Questions On Growth And Valuation - Yahoo Finance
AbbVie's Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade) (NYSE:ABBV) - Seeking Alpha
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense - TipRanks
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates - TechStock²
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. - Barron's
AbbVie forecasts 9.5% sales growth in 2026 amid blockbuster launches and pipeline momentum - MSN
AbbVie stock slides as investors focus on weakness in the aesthetics business - Crain's Chicago Business
AbbVie nears five-month low as Humira drives Q4 beat, not Rinvoq - Seeking Alpha
AMD, AbbVie, Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More Movers - Barron's
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):